(ADPT) Adaptive Biotechnologies Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ADPT) Adaptive Biotechnologies Corporation Complete Analysis Pack
See the Bigger Picture
This Adaptive Biotechnologies Corporation BCG Matrix is a strategic tool for understanding how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before purchase. Buy the full version to get the complete ready-to-use report.
Stars
clonoSEQ multiple myeloma
clonoSEQ is Adaptive Biotechnologies Corporation’s flagship clinical assay for measurable residual disease monitoring in multiple myeloma, a setting where MRD has become a key depth-of-response tool. The hematologic oncology MRD market is still widening as clinicians track remission more closely, and that keeps clonoSEQ in a high-relevance, high-growth lane. Strong clinical adoption makes it a clear Star in the BCG matrix.
clonoSEQ B-cell acute lymphoblastic leukemia
clonoSEQ B-cell acute lymphoblastic leukemia is a Star because it is one of Adaptive Biotechnologies Corporation’s approved hematologic uses, with FDA-cleared MRD testing in adult and pediatric ALL. It can detect disease down to 1 cell in 1,000,000, which fits the rising need for deeper leukemia monitoring. The product is commercially scaled and linked to routine clinical decision-making.
clonoSEQ chronic lymphocytic leukemia
clonoSEQ in chronic lymphocytic leukemia is Adaptive Biotechnologies Corporation’s second major hematology MRD use, after multiple myeloma. CLL is the most common adult leukemia in the U.S., with about 21,250 new cases expected in 2025, so the addressable pool is large. Repeated MRD checks can recur across treatment cycles, which supports recurring test demand. The niche also has strong clinical utility in precision oncology.
clonoSEQ hematologic MRD platform
clonoSEQ is Adaptive Biotechnologies Corporation's core hematologic MRD platform, used for detection and longitudinal monitoring across blood cancers. Its first-mover position in NGS-based immune sequencing diagnostics supports premium positioning, and the MRD market keeps expanding as clinicians use deeper response tracking to guide treatment.
- MRD supports treatment decisions.
- First mover in NGS diagnostics.
- Broader franchise lifts repeat use.
- Growth plus leadership = Star.
immunoSEQ translational research platform
immunoSEQ fits "Star" traits in Adaptive Biotechnologies Corporation's BCG mix: it supports translational research, biomarker discovery, and drug discovery, and the addressable market keeps widening as immune profiling gets more data driven in 2025-2026.
Its value comes from broad research use and repeatable sequencing demand, but scaling still depends on converting platform traffic into durable revenue growth.
- Research and biomarker tool
- Used across multiple workflows
- Market still expanding in 2025-2026
Adaptive Biotechnologies’ Star Assets Power MRD and Immune Profiling Growth
Adaptive Biotechnologies Corporation’s Stars are clonoSEQ in multiple myeloma, ALL, and CLL, plus immunoSEQ in research. These units sit in fast-growing MRD and immune-profiling niches, with clonoSEQ already commercially scaled and immunoSEQ still expanding across 2025-2026 workflows. That mix of growth and leadership fits Star status.
| Asset | 2025-2026 signal | Star cue |
|---|---|---|
| clonoSEQ | MRD to 1 in 1,000,000 | High growth, high share |
| CLL | 21,250 U.S. cases in 2025 | Recurring demand |
| immunoSEQ | Broader research use | Expanding platform |
What is included in the product
Detailed Word Document
Adaptive Biotechnologies’ BCG Matrix shows where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Quick BCG snapshot of Adaptive Biotechnologies to spot cash cows, stars, and underperformers fast.
Reference Sources
Provides a concise source trail to verify Adaptive Biotechnologies assumptions, boosting credibility and speeding investor due diligence.
Cash Cows
immunoSEQ research services
immunoSEQ research services are a repeatable, research-use line with entrenched customers in academia and pharma, so demand is steadier than newer products and not tied to one clinical launch. Adaptive Biotechnologies reported 2024 revenue of about $173 million, and this service can help support cash flow with lower incremental sales spend.
Biomarker discovery contracts
Adaptive Biotechnologies Corporation uses immunoSEQ data for biomarker discovery and immune profiling, and these contracts are usually recurring with pharma and biotech partners. This makes the service line more mature than pipeline bets, so it can help fund growth. In 2024, Adaptive reported about $177 million in revenue, and this cash-generating work helps offset weak spots in newer assets.
Clinical laboratory workflow
The clinical laboratory workflow is a cash cow because Adaptive Biotechnologies already runs a commercial lab for sample processing, sequencing, and reporting. In 2024, revenue was about $176 million, and scale helped gross margin improve. Once fixed lab costs are covered, each extra sample can add profit, so this is a mature base, not a high-risk growth bet.
Established academic customer base
Adaptive Biotechnologies Corporation’s academic and translational research base keeps immune sequencing demand steady, because studies often expand from dozens to hundreds of samples and need follow-on orders. In FY2025, this slower-growth segment still matters because repeat use is tied to active research programs, not one-time purchases. That makes it a classic Cash Cow: stable, recurring revenue with limited growth.
- Repeat orders follow ongoing studies.
- Dataset growth supports reorders.
- Stable, low-growth revenue base.
Repeat MRD monitoring orders
Repeat MRD monitoring orders are a cash cow for Adaptive Biotechnologies Corporation because hematologic oncology patients often need serial clonoSEQ tests across treatment and follow-up. Once a center adopts the assay, the same patient can drive recurring orders, so revenue is steadier than in early-stage programs.
- Serial testing supports repeat orders.
- Adoption raises account-level stickiness.
- Recurring use makes cash flow more mature.
Adaptive’s Cash Cow: Sticky ImmunoSEQ and clonoSEQ Revenue
Adaptive Biotechnologies Corporation’s cash cows are immunoSEQ research services and serial clonoSEQ monitoring: both are repeat-use, low-growth lines with sticky accounts. FY2024 revenue was about $176 million, and recurring lab volume helps spread fixed costs, so these lines can keep cash flowing while newer bets scale.
| Cash cow | Why it fits | Latest revenue |
|---|---|---|
| immunoSEQ and clonoSEQ | Repeat orders, steady demand | About $176 million FY2024 |
What You See Is What You Get
Adaptive Biotechnologies Corporation Reference Sources
The Adaptive Biotechnologies Corporation BCG Matrix preview you see is the exact same document you’ll receive after purchase. There are no demo pages or hidden edits—just the full, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategic planning. What you preview is what you get.
Dogs
T-Detect COVID
T-Detect COVID fits the Dogs bucket: it was built to confirm past COVID-19 infection, but demand fell fast after the 2020-2022 peak and the market became far less attractive. By end-2025, it looks like a low-growth, low-share asset with little pricing power and no clear path to scale. Adaptive Biotechnologies Corporation has shifted attention to higher-value immune diagnostics, while COVID serology demand has normalized sharply from pandemic levels.
immunoSEQ T-MAP COVID
immunoSEQ T-MAP COVID was a pandemic-only assay for measuring T-cell responses to COVID-19 vaccines, so its market was tied to 2020-2022 demand. By 2025, COVID testing had normalized, and the product no longer had strong strategic pull inside Adaptive Biotechnologies Corporation’s portfolio. In BCG terms, it fits a Dog: low growth, weak long-term fit, and limited capital priority.
COVID infection confirmation testing
Adaptive Biotechnologies Corporation's COVID infection confirmation testing fits Dog territory because it rode a one-time 2020-2022 surge that has since normalized. With the WHO ending the global COVID-19 public health emergency on May 5, 2023, demand shifted to a much smaller endemic testing base, so long-term growth is weak. That makes this offer low-growth, low-share, and a poor capital allocator.
COVID vaccine-response services
Adaptive Biotechnologies Corporation's COVID vaccine-response services sit in a small, narrow niche. They were useful during the 2021-2022 public health surge, but by fiscal 2025 they no longer look like a core growth engine.
In BCG terms, this is a Dog: low growth, limited scale, and weak strategic priority. One line says it all: the pandemic demand spike faded, and this service line did too.
Niche vaccine immune-response service
Useful during pandemic demand peaks
By 2025, not a growth driver
Fits Dog quadrant logic
Pandemic-specific diagnostics
Adaptive Biotechnologies Corporation’s pandemic-specific diagnostics are a Dogs asset: the COVID testing market is crowded, pricing is weak, and demand has not returned to 2020-2021 peak levels. These products are unlikely to scale into a durable growth engine, so they can absorb cash without lifting long-run value. The portfolio looks like a harvest-and-contain line, not a growth driver.
- Low rebound odds
- Heavy competition
- Cash trap risk
Adaptive Biotechnologies’ COVID Assays: From Pandemic Surge to BCG Dogs
Adaptive Biotechnologies Corporation’s Dogs are its pandemic-era COVID assays: demand faded after the 2020-2022 spike, and the WHO ended the global emergency on 2023-05-05. By fiscal 2025, these offers had low growth, weak pricing power, and no clear scale path. In BCG terms, they are cash-drain, low-priority assets.
| Offer | 2025 view | BCG |
|---|---|---|
| T-Detect COVID | Endemic demand, weak growth | Dog |
Question Marks
Microsoft multi-disease blood test
Adaptive Biotechnologies Corporation’s Microsoft-linked multi-disease blood test is a Question Mark: it targets early detection from one blood sample, but commercial share is still unproven. The opportunity is large, with the global in vitro diagnostics market expected to reach about $115 billion by 2027, yet Adaptive Biotechnologies Corporation still posted only $179 million in 2024 revenue and a net loss, showing scale is not locked in. If adoption rises, this could move fast from R&D optionality to a growth engine.
Genentech neoantigen T-cell therapies
Adaptive Biotechnologies Corporation’s Genentech neoantigen T-cell therapy program is a joint effort to build cancer treatments that target patient-specific tumor mutations, but it is still in development, not revenue-generating. The broader cell therapy market was valued at about $5 billion in 2024 and is projected to grow at a double-digit CAGR through 2030, so the upside is real. Still, the program needs heavy capital, clinical proof, and manufacturing scale to move from Question Mark to Star.
Autoimmune diagnostics pipeline
Adaptive Biotechnologies Corporation’s autoimmune diagnostics pipeline targets a huge, medically important market: autoimmune disease affects about 50 million Americans and includes more than 80 conditions. The opportunity is real, but Adaptive has not yet built dominant share in this space, so the franchise still fits a Question Mark in the BCG Matrix.
Its immune-sequencing platform can support earlier diagnosis and monitoring, but commercial scale is still limited versus the size of the unmet need. Until Adaptive proves repeatable revenue growth and stronger adoption, this pipeline remains high-upside but unproven.
Infectious disease pipeline
Adaptive Biotechnologies Corporation’s infectious disease pipeline is a real upside case, because the global diagnostics market is large and recurring. But beyond COVID, its commercial traction is still not proven, so the BCG Matrix fits it closer to a Question Mark than a Star. The upside is there, but so is the risk that new assays do not scale fast enough.
- Large market, weak proof
- Beyond-COVID demand is real
- Execution risk stays high
Non-hematologic oncology expansion
Adaptive Biotechnologies Corporation’s Question Mark is non-hematologic oncology: its revenue engine is still blood cancers, while solid-tumor testing and monitoring remain early-stage. The upside is real because broader minimal residual disease and cancer-detection use cases can grow fast, but share outside hematologic oncology is still small. In other words, the market is bigger than its current footprint.
- Core revenue: hematologic oncology
- Solid tumors: high-growth option
- Current share: still low
Adaptive Biotechnologies: Big Upside, Unproven Share
Adaptive Biotechnologies Corporation’s Question Marks have big upside but weak proof: Microsoft-linked early detection, Genentech neoantigen therapy, and autoimmune and infectious disease tests are still not dominant. In FY2024, revenue was $179 million and the company still posted a net loss, so scale is not locked in. The bet is clear: strong markets, but share is still unproven.
| Area | Signal |
|---|---|
| FY2024 revenue | $179 million |
| Status | High-upside, low-share |
| Risk | Clinical and adoption execution |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.